Biotech entity
Every one of those 1 sits in a single category, clinical-trial. AbbVie is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.
Last mentioned: Aug 1, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. AbbVie is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. Their average consequence score of 6 runs above the beat's 5.7 for that window. DuoBody appears in 1 tracked Biotech story from August 1, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering DuoBody. Shared-story counts are live from our verified record — not editorial picks.
Clarification on US Primary Endpoint
Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
EHA 2026 Presentation
Additional study results presented at the European Hematology Association Congress.
Topline Results Announced
Genmab and AbbVie released initial data from the Phase 3 EPCORE DLBCL-1 trial.
The Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its US overall survival endpoint, jeopardizing full approval and the drug's growing $300 million annual sales. This clarification deepens the competitive threat from other bispecifics with survival data.
Source: finanznachrichten.de · stockhouse.com
DuoBody is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
